Janus Kinase Inhibitor

By most metrics, modern rheumatology drugs are safer and more effective than those used in previous eras.

Janus kinase inhibitors have delivered on some, but not all, of the promises that were expected of them upon approval in 2012, a speaker said at EULAR 2022 Congress.

DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.

DESTIN, Fla. — Switching to a different drug class with a different mechanism of action can improve response in patients with difficult-to-treat rheumatoid arthritis, according to Janet Pope, MD, of Western University, in Ontario, Canada.

DESTIN, Fla. — Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022.

DESTIN, Fla. — An ever-increasing array of treatment options is allowing rheumatologists to target specific disease domains in their patients with psoriatic arthritis, according to a speaker at the Congress of Clinical Rheumatology East.

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.

Despite some safety concerns, Janus kinase, or JAK, inhibitors, are carving out a place as important treatment options for a number of autoimmune diseases, including psoriatic arthritis.

Baricitinib reduces structural joint damage progression in rheumatoid arthritis even among patients with who continue to exhibit moderate or high disease activity, according to data published in Annals of the Rheumatic Diseases.

WAILEA, Hawaii — In this video perspective from Maui Derm for Dermatologists, Jerry Shapiro, MD, FAAD, reviews treatment options for alopecia areata, androgenetic alopecia and frontal fibrosing alopecia.